NCT03129113View on ClinicalTrials.gov

Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

November 5, 2020

Study Completion Date

November 6, 2020

Conditions
Hepatic SteatosisHIV-1-infection
Interventions
DRUG

Maraviroc

1:1:1:1 randomisation to one of four arms for 48 weeks

DRUG

Metformin

1:1:1:1 randomisation to one of four arms for 48 weeks

Trial Locations (6)

E1 1FR

Royal London Hospital, London

NW3 2QG

Royal Free Hospital, London

SE1 9RT

St Thomas' Hospital, London

SE5 9RJ

King's College Hospital, London

W2 1NY

St Mary's Hospital, London

WC1E 6JB

UCL Mortimer Market Centre, London

Sponsors
All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

collaborator

ViiV Healthcare

INDUSTRY

collaborator

Royal Free Hospital NHS Foundation Trust

OTHER

lead

University College, London

OTHER